| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DXCM | Common Stock | Sale | -$1.5M | -2.5K | -73.14% | $600.03 | 918 | Oct 29, 2021 | Direct | F1, F2, F3 |
| holding | DXCM | Common Stock | 7.59K | Oct 29, 2021 | by Trust |
| Id | Content |
|---|---|
| F1 | On March 4, 2021, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The sale of shares set forth above were pursuant to the 10b5-1 Plan. |
| F2 | This transaction was executed in multiple trades at prices ranging from $600.00 to $600.295. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| F3 | Included in this number are 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting. |